Exploring Structural Uncertainty in Model-Based Economic Evaluations

Given the inherent uncertainty in estimates produced by decision analytic models, the assessment of uncertainty in model-based evaluations is an essential part of the decision-making process. Although the impact of uncertainty around the choice of model structure and making incorrect structural assumptions on model predictions is noted, relatively little attention has been paid to characterising this type of uncertainty in guidelines developed by national funding bodies such as the Australian Pharmaceutical Benefits Advisory Committee (PBAC). The absence of a detailed description and evaluation of structural uncertainty can add further uncertainty to the decision-making process, with potential impact on the quality of funding decisions. This paper provides a summary of key elements of structural uncertainty describing why it matters and how it could be characterised. Five alternative approaches to characterising structural uncertainty are discussed, including scenario analysis, model selection, model averaging, parameterization and discrepancy. We argue that the potential effect of structural uncertainty on model predictions should be considered in submissions to national funding bodies; however, the characterisation of structural uncertainty is not well defined within the guidelines of these bodies. There has been little consideration of the forms of structural sensitivity analysis that might best inform applied decision-making processes, and empirical research in this area is required.

[1]  N. Lazar,et al.  Methods and Criteria for Model Selection , 2004 .

[2]  W. Edmunds,et al.  Impact of Model, Methodological, and Parameter Uncertainty in the Economic Analysis of Vaccination Programs , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  Joshua A. Salomon,et al.  Exploring Model Uncertainty in Economic Evaluation of Health Interventions: The Example of Rotavirus Vaccination in Vietnam , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[4]  Karl Claxton,et al.  Defining and characterising structural uncertainty in decision analytic models , 2006 .

[5]  M. Sculpher,et al.  Modelling the long‐term cost‐effectiveness of endovascular or open repair for abdominal aortic aneurysm , 2007, The British journal of surgery.

[6]  Andrew H. Briggs,et al.  Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.

[7]  A. O'Hagan,et al.  Bayesian calibration of computer models , 2001 .

[8]  David R. Anderson,et al.  Model selection and multimodel inference : a practical information-theoretic approach , 2003 .

[9]  Jonathan Karnon,et al.  Calibrating Models in Economic Evaluation , 2012, PharmacoEconomics.

[10]  Malcolm J Price,et al.  Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  A. O'Hagan,et al.  Statistical Methods for Eliciting Probability Distributions , 2005 .

[12]  M C Downer,et al.  The cost-effectiveness of screening for oral cancer in primary care. , 2006, Health technology assessment.

[13]  J. Schellens,et al.  The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance , 2013, PharmacoEconomics.

[14]  Jonathan Karnon,et al.  Specification and Implementation of Decision Analytic Model Structures for Economic Evaluation of Health Care Technologies , 2014 .

[15]  Simon G Thompson,et al.  Uncertainty and validation of health economic decision models. , 2009, Health economics.

[16]  Karl Claxton,et al.  Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[17]  Karl Claxton,et al.  A Framework for Addressing Structural Uncertainty in Decision Models , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  David Draper,et al.  Assessment and Propagation of Model Uncertainty , 2011 .

[19]  Karl Claxton,et al.  Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  J Gabbay,et al.  Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach. , 2004, Health technology assessment.

[21]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[22]  Jörgen Möller,et al.  Decision-Analytic Models: Current Methodological Challenges , 2014, PharmacoEconomics.

[23]  Srikanta Mishra,et al.  Model Averaging Techniques for Quantifying Conceptual Model Uncertainty , 2010, Ground water.

[24]  Simon G Thompson,et al.  Structural and parameter uncertainty in Bayesian cost-effectiveness models , 2010, Journal of the Royal Statistical Society. Series C, Applied statistics.

[25]  J. Bryant,et al.  Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. , 2010, Health technology assessment.

[26]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .

[27]  Jonathan Karnon,et al.  A proposed model for economic evaluations of major depressive disorder , 2012, The European Journal of Health Economics.

[28]  Simon G Thompson,et al.  Accounting for uncertainty in health economic decision models by using model averaging , 2009, Journal of the Royal Statistical Society. Series A,.

[29]  Jeremy E. Oakley,et al.  Managing structural uncertainty in health economic decision models: a discrepancy approach , 2012 .

[30]  S. Palmer,et al.  Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. , 2004, Health technology assessment.

[31]  R. Mori,et al.  Diagnosis of UTI: results of an evidence based approach to guideline development carried out for the National Institute for Health and Clinical Excellence (NICE) , 2008 .